Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Atugen and Asinex enter cancer discovery deal
Atugen will contribute its target discovery and in-vivo screening know-how while drug design, medicinal chemistry and in-vitro screening expertise will be provided by Asinex. The novel kinase target
Atugen will contribute its target discovery and in-vivo screening know-how while drug design, medicinal chemistry and in-vitro screening expertise will be provided by Asinex. The novel kinase target
If successfully developed, the product would address the multi-billion dollar market opportunity for the prevention and treatment of venous thrombosis and for the prevention and treatment of thromboembolic
The merger will integrate Syrrx’s technologies and R&D pipeline into Takeda and establish a discovery research presence for Takeda in the US. This relationship is expected to help
RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke. There are currently no drugs on
Anidulafungin was superior to Diflucan (fluconazole) in the primary endpoint – global response at the end of intravenous therapy. Anidulafungin also demonstrated superiority in all secondary endpoints, including
In the trial, Phenserine, which is in development for mild to moderate Alzheimer’s disease (AD), failed to result in a statistically significant improvement over placebo for the protocol’s
The national antiviral stockpile will be used to treat identified priority groups, agreed upon by a national expert advisory committee on pandemic influenza. The federal contribution goes towards
The researchers stated that, because oral therapy can be started more quickly and is less painful than intravenous (IV) treatment, it should be the preferred treatment for children
The varicella vaccine is almost 90% effective against chickenpox but its impact on herpes zoster (shingles) is unknown and needs wider surveillance, according to the researchers. The varicella
Reports so far suggest that the FDA believes the cardiovascular risks that resulted in Merck’s voluntary withdrawal of Vioxx (rofecoxib) are a class effect. As well as looking